Europe Forced Oscillometry Market is expected to reach US$ 24,847.7 Thousand by 2034

According to The Insight Partners\' research, the Europe Forced Oscillometry Market was valued at US$ 15,193.7 Thousand in 2025 and is expected to reach US$ 24,847.7 Thousand by 2034, registering a CAGR of 5.7% from 2026 to 2034.

Government initiatives, reimbursement expansion, and the rise of hybrid oscillometry systems are among the critical factors attributed to driving the Europe forced oscillometry market growth.

The World Health Organization\'s Package of Essential Noncommunicable Disease Interventions (WHO PEN) for primary health care explicitly includes guidance on the diagnosis and long-term management of asthma and COPD in low-resource settings, creating a policy foundation for effort-independent tests such as oscillometry in community clinics. The NHS Long Term Plan (2019-present), supported by national prevention programmes such as the NHS Health Check, NHS Diabetes Prevention Programme, and cancer screening initiatives focuses on reducing the burden of major NCDs, including cardiovascular disease, diabetes, cancer, and chronic respiratory diseases, through early detection, risk-factor reduction, preventive care, and integrated management within primary healthcare. It also uses population health data and digital health tools to improve prevention, diagnosis, and long-term disease management across England. Similar NCD strategies in other emerging economies align with WHO PEN recommendations, promoting primary-care strengthening and inclusion of advanced yet simple diagnostics.

The European Respiratory Society\'s technical standards for oscillometry support guideline development, while clinical evidence-such as the superior sensitivity of oscillometry for small-airway disease-bolsters arguments for reimbursement and adoption. As governments expand universal health coverage, telemedicine reimbursement, and chronic-disease screening programmes, forced oscillometry gains traction as a cost-effective, patient-friendly complement to spirometry. This policy momentum, combined with dedicated CPT coding and international primary-care frameworks, removes financial and regulatory barriers, enabling wider deployment in both high-income and low-resource health systems and improving outcomes for millions living with chronic respiratory diseases

On the contrary, the high equipment and maintenance costs hamper the growth of the Europe forced oscillometry market.

Europe Forced Oscillometry Market Segmentation Analysis:

• By Product, the Europe Forced Oscillometry Market is segmented into Device and Accessories. The Device segment is projected to expand at a CAGR of 4.6% during 2026 - 2034.
• By Device for Product, the Europe Forced Oscillometry Market is segmented into Desktop and Portable. The Desktop segment is projected to expand at a CAGR of 4.4% during 2026 - 2034.
• By Accessories for Product, the Europe Forced Oscillometry Market is segmented into Filters, Nose Clip, Support Arms, and Other Accessories. The Filters segment is projected to expand at a CAGR of 8.3% during 2026 - 2034.
• By Application, the Europe Forced Oscillometry Market is segmented into Asthma, COPD, and Other Applications. The Asthma segment is projected to expand at a CAGR of 6.1% during 2026 - 2034.
• By End User, the Europe Forced Oscillometry Market is segmented into Hospitals and Clinics, Diagnostic Laboratories, and Other End users. The Hospitals and Clinics segment is projected to expand at a CAGR of 5.9% during 2026 - 2034.

By country, the Europe Forced Oscillometry Market is categorized into Germany, the United Kingdom, France, Italy, Spain, and the Rest of Europe. Germany is projected to expand at a CAGR of 6.1% during 2026 - 2034.

Key players operating in the Forced Oscillometry Market are COSMED Srl, Chest MI Inc, Morgan Scientific Inc, THORASYS Thoracic Medical Systems Inc., Jaeger Medical GmbH, IngMar Medical, GANSHORN Medizin Electronic GmbH, Lothar Medical GmbH, Cognita Labs, LLC, and RESTECH srl, among others.

• In December 2025, COSMED S.r.l., a global leader in Cardiopulmonary diagnostics, Metabolic assessment solutions, and Body Composition technologies, is pleased to announce the acquisition of Ergometrix S.A., a long-established Spanish distributor specialized in electronic equipment for the healthcare and rehabilitation sectors.